Critical Clinical Trial Updates Expected in 3Q
Ten clinical trial data readouts to watch for in the third quarter of 2017 that are expected to shift stocks and potentially change standard of care options in some disease areas.
You may also be interested in...
Apellis Pharmaceuticals' lead product APL-2 for geographic atrophy, a progressed form of age-related macular degeneration, has met its primary endpoint in a Phase II trial with the company planning to begin Phase III trials in 2018.
Zynerba’s gel formulation of cannabidiol has disappointed in top-line data from a Phase II study in epilepsy patients with focal seizures, but some signals of efficacy in a companion study, and expected data from studies in two other indications, might influence future development plans.
As the CEO of Axovant, David Hung is back where he started with Medivation – working on a drug for Alzheimer's disease.